Advertisement

Topics

FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE

21:58 EST 12 Nov 2017 | RTTNews

Today's Daily Dose brings you news about Arena's progress in phase II study of Etrasimod in ulcerative colitis; expanded FDA approval of Bristol-Myers' leukemia drug Sprycel; voluntarily delisting of Mylan's ordinary shares from the Tel Aviv Stock Exchange and Vanda's disappointment over Fanaptum's failure to win the CHMP's backing.

Original Article: FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE

NEXT ARTICLE

More From BioPortfolio on "FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...